Cumberland Pharmaceuticals Inc. (CPIX)
USD 4.19
(-0.95%)
USD 4.19
(-0.95%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 4.6 Million USD | -50.96% |
| 2022 | 9.39 Million USD | 11.5% |
| 2021 | 8.42 Million USD | -20.76% |
| 2020 | 10.63 Million USD | 19.92% |
| 2019 | 8.87 Million USD | -68.12% |
| 2018 | 27.82 Million USD | 313.0% |
| 2017 | 6.73 Million USD | 25.43% |
| 2016 | 5.37 Million USD | 25.8% |
| 2015 | 4.27 Million USD | -23.75% |
| 2014 | 5.6 Million USD | -2.14% |
| 2013 | 5.72 Million USD | -7.97% |
| 2012 | 6.21 Million USD | 7.68% |
| 2011 | 5.77 Million USD | -24.85% |
| 2010 | 7.68 Million USD | 59.32% |
| 2009 | 4.82 Million USD | 173.6% |
| 2008 | 1.76 Million USD | 85.73% |
| 2007 | 949.1 Thousand USD | 41.43% |
| 2006 | 671.09 Thousand USD | 22.83% |
| 2005 | 546.38 Thousand USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 4.32 Million USD | -6.11% |
| 2024 Q2 | 4.3 Million USD | -0.59% |
| 2023 Q4 | 4.6 Million USD | -46.84% |
| 2023 Q3 | 8.67 Million USD | -20.66% |
| 2023 Q1 | 10.18 Million USD | 8.3% |
| 2023 Q2 | 10.92 Million USD | 7.35% |
| 2023 FY | 4.6 Million USD | -50.96% |
| 2022 FY | 9.39 Million USD | 11.5% |
| 2022 Q1 | 9.87 Million USD | 17.19% |
| 2022 Q2 | 9.42 Million USD | -4.64% |
| 2022 Q3 | 10.64 Million USD | 13.03% |
| 2022 Q4 | 9.39 Million USD | -11.72% |
| 2021 FY | 8.42 Million USD | -20.76% |
| 2021 Q2 | 10.1 Million USD | 0.93% |
| 2021 Q4 | 8.42 Million USD | -17.86% |
| 2021 Q1 | 10.01 Million USD | -5.9% |
| 2021 Q3 | 10.26 Million USD | 1.57% |
| 2020 Q3 | 10.08 Million USD | 32.16% |
| 2020 Q4 | 10.63 Million USD | 5.53% |
| 2020 FY | 10.63 Million USD | 19.92% |
| 2020 Q1 | 8.15 Million USD | -8.13% |
| 2020 Q2 | 7.62 Million USD | -6.42% |
| 2019 FY | 8.87 Million USD | -68.12% |
| 2019 Q4 | 8.87 Million USD | -10.07% |
| 2019 Q2 | 10.64 Million USD | -5.42% |
| 2019 Q3 | 9.86 Million USD | -7.37% |
| 2019 Q1 | 11.25 Million USD | -59.54% |
| 2018 FY | 27.82 Million USD | 313.0% |
| 2018 Q1 | 6.66 Million USD | -1.13% |
| 2018 Q3 | 6.42 Million USD | -12.51% |
| 2018 Q4 | 27.82 Million USD | 333.01% |
| 2018 Q2 | 7.34 Million USD | 10.27% |
| 2017 FY | 6.73 Million USD | 25.43% |
| 2017 Q2 | 5.55 Million USD | -1.64% |
| 2017 Q1 | 5.64 Million USD | 5.12% |
| 2017 Q4 | 6.73 Million USD | 15.03% |
| 2017 Q3 | 5.85 Million USD | 5.46% |
| 2016 Q1 | 4.07 Million USD | -4.6% |
| 2016 FY | 5.37 Million USD | 25.8% |
| 2016 Q3 | 4.98 Million USD | 1.25% |
| 2016 Q2 | 4.92 Million USD | 20.82% |
| 2016 Q4 | 5.37 Million USD | 7.8% |
| 2015 Q2 | 4.79 Million USD | 3.48% |
| 2015 FY | 4.27 Million USD | -23.75% |
| 2015 Q4 | 4.27 Million USD | 1.52% |
| 2015 Q3 | 4.2 Million USD | -12.29% |
| 2015 Q1 | 4.63 Million USD | -17.25% |
| 2014 Q2 | 6.99 Million USD | -5.73% |
| 2014 Q1 | 7.42 Million USD | 29.69% |
| 2014 Q3 | 6.13 Million USD | -12.38% |
| 2014 FY | 5.6 Million USD | -2.14% |
| 2014 Q4 | 5.6 Million USD | -8.65% |
| 2013 Q2 | 6.09 Million USD | 1.71% |
| 2013 Q3 | 5.43 Million USD | -10.81% |
| 2013 Q4 | 5.72 Million USD | 5.28% |
| 2013 FY | 5.72 Million USD | -7.97% |
| 2013 Q1 | 5.99 Million USD | -3.64% |
| 2012 Q3 | 7.51 Million USD | 2.67% |
| 2012 Q4 | 6.21 Million USD | -17.22% |
| 2012 FY | 6.21 Million USD | 7.68% |
| 2012 Q1 | 6 Million USD | 4.0% |
| 2012 Q2 | 7.31 Million USD | 21.83% |
| 2011 Q2 | 7.45 Million USD | -4.72% |
| 2011 Q4 | 5.77 Million USD | -16.0% |
| 2011 Q3 | 6.87 Million USD | -7.76% |
| 2011 FY | 5.77 Million USD | -24.85% |
| 2011 Q1 | 7.82 Million USD | 1.81% |
| 2010 FY | 7.68 Million USD | 59.32% |
| 2010 Q2 | 7.96 Million USD | 7.57% |
| 2010 Q1 | 7.4 Million USD | 53.57% |
| 2010 Q3 | 7.64 Million USD | -4.03% |
| 2010 Q4 | 7.68 Million USD | 0.49% |
| 2009 Q1 | 1.34 Million USD | -23.6% |
| 2009 Q3 | 1.68 Million USD | 52.26% |
| 2009 Q2 | 1.1 Million USD | -17.7% |
| 2009 Q4 | 4.82 Million USD | 185.78% |
| 2009 FY | 4.82 Million USD | 173.6% |
| 2008 Q4 | 1.76 Million USD | -1.99% |
| 2008 Q3 | 1.79 Million USD | 89.72% |
| 2008 Q1 | 1.17 Million USD | 23.67% |
| 2008 Q2 | 947.99 Thousand USD | -19.24% |
| 2008 FY | 1.76 Million USD | 85.73% |
| 2007 Q3 | 1.03 Million USD | -19.4% |
| 2007 FY | 949.1 Thousand USD | 41.43% |
| 2007 Q2 | 1.28 Million USD | 30.13% |
| 2007 Q1 | 988.06 Thousand USD | 47.23% |
| 2007 Q4 | 949.1 Thousand USD | -8.41% |
| 2006 Q4 | 671.09 Thousand USD | 0.0% |
| 2006 FY | 671.09 Thousand USD | 22.83% |
| 2005 FY | 546.38 Thousand USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Cosmos Health Inc. | 4.78 Million USD | 3.752% |
| Safety Shot Inc | 1.86 Million USD | -146.536% |
| Bright Green Corporation | - USD | -Infinity% |
| Embecta Corp. | 152.1 Million USD | 96.97% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 95.855% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | 31.905% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | 85.744% |
| Dynavax Technologies Corporation | 53.29 Million USD | 91.35% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 92.976% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | 60.424% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 95.583% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 19.624% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 19.624% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -469.228% |
| Journey Medical Corporation | 10.2 Million USD | 54.837% |
| Alpha Teknova, Inc. | 11.59 Million USD | 60.244% |
| Procaps Group, S.A. | 96.83 Million USD | 95.24% |
| Theratechnologies Inc. | 6.06 Million USD | 24.013% |
| Harrow Health, Inc. | 10.86 Million USD | 57.584% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -69.524% |
| Biofrontera Inc. | 10.9 Million USD | 57.743% |
| DURECT Corporation | 2.21 Million USD | -107.722% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 94.045% |
| Cronos Group Inc. | 30.33 Million USD | 84.807% |
| OptiNose, Inc. | 8.05 Million USD | 42.755% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -460936100.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | 19.12% |
| Organogenesis Holdings Inc. | 28.25 Million USD | 83.685% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -72.177% |
| Radius Health, Inc. | 278.64 Million USD | 98.346% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -37.87% |
| ProPhase Labs, Inc. | 3.84 Million USD | -20.004% |
| Phibro Animal Health Corporation | 265.91 Million USD | 98.267% |
| Procaps Group S.A. | 96.83 Million USD | 95.24% |
| Alvotech | 74.43 Million USD | 93.807% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 99.867% |
| Rockwell Medical, Inc. | 5.87 Million USD | 21.489% |
| Aytu BioPharma, Inc. | 12.63 Million USD | 63.513% |
| SIGA Technologies, Inc. | 64.21 Million USD | 92.822% |
| Tilray Brands, Inc. | 252.08 Million USD | 98.172% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | 88.471% |
| Shineco, Inc. | 1.58 Million USD | -190.166% |
| PetIQ, Inc. | 159.3 Million USD | 97.107% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 3117.033% |
| Incannex Healthcare Limited | -10.01 Million USD | 146.025% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 87.965% |
| Alimera Sciences, Inc. | 1.87 Million USD | -145.309% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | 87.769% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -186.226% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | -2.819% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -1712.198% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | 55.594% |
| Hempacco Co., Inc. | 2.54 Million USD | -81.283% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 93.807% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 90.356% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 92.801% |
| Currenc Group, Inc. | 732.91 Thousand USD | -528.912% |
| Kamada Ltd. | 87.74 Million USD | 94.747% |
| Indivior PLC | 141.79 Million USD | 96.749% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -856.617% |
| Flora Growth Corp. | 8.5 Million USD | 45.823% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -1712.198% |
| Evolus, Inc. | 10.99 Million USD | 58.089% |
| HUTCHMED (China) Limited | 50.25 Million USD | 90.829% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 95.645% |
| Akanda Corp. | 1.28 Million USD | -258.177% |